← Arcus Biosciences, Inc. RCUS
Market Price
$29.46
Market Cap
$3.63B
P/E Ratio
N/A
Revenue (FY 2025)
↓-35.3% YoY
$33.00M
3-Yr CAGR: -33.5%
Net Income
↓-24.7% YoY
-$353.00M
Net Margin: -1,069.7%
Free Cash Flow
↓-175.0% YoY
-$484.00M
FCF Yield: -13.33%
EPS (Diluted)
↓-4.8% YoY
$-3.29
Basic: $-3.29
Return on Equity
Efficiency
-55.9%
ROA: -31.0%
📊 Multi-Year Historical Performance & Trends
Financial Performance History
Revenue, Net Income & Free Cash Flow
Margins Trend (%)
Gross, Operating & Net Margins
Balance Sheet Strength
Cash, Debt & Equity
Cash Flow Generation
Operating Cash Flow vs CapEx vs FCF
📈 Year-over-Year (YoY) Growth History (RCUS)
All monetary values in millions ($M)
⚠️ YoY Data Quality Alert
- FY 2018: Revenue YoY (+491.2%) is identical to Gross Profit YoY (+491.2%). Verify the underlying Revenue and Gross Profit values for FY 2018 and FY 2017.
- FY 2019: Revenue YoY (+79.6%) is identical to Gross Profit YoY (+79.6%). Verify the underlying Revenue and Gross Profit values for FY 2019 and FY 2018.
- FY 2020: Revenue YoY (+416.8%) is identical to Gross Profit YoY (+416.8%). Verify the underlying Revenue and Gross Profit values for FY 2020 and FY 2019.
| Fiscal Year | Revenue | Revenue YoY | Gross Profit | Net Income | Net Inc YoY | Diluted EPS | EPS YoY | Op. Cash Flow | Free Cash Flow | FCF YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| FY 2011 | — | — | — | — | — | — | — | — | — | — |
| FY 2016 | — | — | — | $-18.0M | — | — | — | $-12.9M | $-17.0M | — |
| FY 2017 | $1.4M | — | $1.4M | $-53.1M | -195.4% | — | — | $-25.1M | $-30.6M | -79.4% |
| FY 2018 | $8.4M | +491.2% | $8.4M | $-49.6M | +6.6% | — | — | $-43.0M | $-46.7M | -52.9% |
| FY 2019 | $15.0M | +79.6% | $15.0M | $-84.7M | -70.8% | — | — | $-73.5M | $-75.4M | -61.3% |
| FY 2020 | $77.5M | +416.8% | $77.5M | $-122.9M | -45.0% | — | — | $111.2M | $108.1M | +243.4% |
| FY 2021 | $382.9M | +393.9% | $126.5M | $52.8M | +143.0% | $0.71 | — | $-256.2M | $-282.2M | -361.1% |
| FY 2022 | $112.0M | -70.7% | $110.0M | $-267.0M | -605.4% | $-3.71 | -622.5% | $438.0M | $432.0M | +253.1% |
| FY 2023 | $117.0M | +4.5% | $115.0M | $-307.0M | -15.0% | $-4.15 | -11.9% | $-306.0M | $-330.0M | -176.4% |
| FY 2024 | $51.0M | -56.4% | $47.0M | $-283.0M | +7.8% | $-3.14 | +24.3% | $-170.0M | $-176.0M | +46.7% |
| FY 2025 | $33.0M | -35.3% | $24.0M | $-353.0M | -24.7% | $-3.29 | -4.8% | $-482.0M | $-484.0M | -175.0% |
Valuation
Market Price
$29.46
Market Cap
$3.63B
Enterprise Value
$3.52B
P/E Ratio
N/A
P/B Ratio
5.87
FCF Yield
-13.33%
Dividend Yield
N/A
Shares Outstanding
Profitability & Margins
Gross Margin
72.73%
Operating Margin
-1,169.70%
Net Margin
-1,069.70%
Return on Equity (ROE)
-55.94%
Return on Assets (ROA)
-30.99%
Asset Turnover
0.03x
Revenue 3-Yr CAGR
-33.46%
Financial Health & Liquidity
Current Ratio
0.06
Cash Ratio
0.96
Debt / Equity
0.177
Debt / Assets
0.098
Cash & Equivalents
$222.00M
Total Debt
$112.00M
Book Value / Share
$5.02
Cash Flow Efficiency
Operating Cash Flow
-$482.00M
Capital Expenditures (CapEx)
$2.00M
Free Cash Flow
-$484.00M
OCF / Revenue
-1,460.61%
FCF / Revenue
-1,466.67%
FCF 3-Yr CAGR
N/A
Per Share Metrics
EPS (Diluted)
$-3.29
EPS (Basic)
$-3.29
Dividends / Share
N/A
Book Value / Share
$5.02
EPS YoY Growth
-4.78%
Balance Sheet (FY 2025)
Total Assets
$1.14B
Total Liabilities
$1.14B
Stockholders' Equity
$631.00M
Current Assets
$15.00M
Current Liabilities
$231.00M